VanEck Biotech ETFVanEck Biotech ETFVanEck Biotech ETF

VanEck Biotech ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪439.19 M‬USD
Fund flows (1Y)
‪−59.32 M‬USD
Dividend yield (indicated)
0.41%
Discount/Premium to NAV
0.4%

About VanEck Biotech ETF


Issuer
Van Eck Associates Corp.
Brand
VanEck
Expense ratio
0.35%
Home page
Inception date
Dec 20, 2011
Index tracked
MVIS US Listed Biotech 25
Management style
Passive
BBH offers a more concentrated take on the global biotech industry. Although the space is already dominated by US firms, the fund aims to select just 25 US listed companies by market cap, also weighing each constituent by market cap. The underlying index has a flexible definition of biotech, encompassing companies engaged primarily in research (including research contractors) and development as well as production, marketing and sales of drugs based on genetic analysis and diagnostic equipment, excluding pharmacies. Also, despite capping its issuers to a maximum of 20%, the fund may still be top heavy due to the indexs concentrated nature. Overall, BBH is a viable take on this market. The index is reviewed semi-annually.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Biotechnology
Strategy
Vanilla
Weighting scheme
Market cap
Selection criteria
Market cap

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of November 7, 2024
Exposure type
StocksBonds, Cash & Other
Health Technology
Stocks99.95%
Health Technology89.91%
Commercial Services5.32%
Health Services4.72%
Bonds, Cash & Other0.05%
Cash0.05%
Stock breakdown by region
100%
North America100.00%
Latin America0.00%
Europe0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows